Transformative solutions to serve the bladder cancer community
Based on the Photocure Technology® platform, Photocure has developed and commercialized Hexvix® and Cysview® for use in bladder cancer.
Cysview® is the trademark in the U.S. and Canada, and Hexvix® is the trademark in all other countries.
Hexvix® (hexaminolevulinate 85mg)
Cysview® (hexaminolevulinate HCL)
HIVEC® (Hyperthermic IntraVEsical Chemotherapy)
Additionally, Photocure distributes Combat BRS and Combat BRS kits for the HIVEC® procedure in the Nordics, an innovative recirculation system for the delivery of hyperthermic intravesical chemotherapy in the treatment of non-muscle invasive bladder cancer (NMIBC).
Products Divested or Out-Licensed
Own-developed non-urology products divested or out-licensed:
Based on Photocure Technology®, the company developed and commercialized Metvix, a product for non-melanoma skin cancer and actinic keratosis. The product was divested to Galderma S.A. in 2009.
Photocure developed a cosmetic product to improve the overall appearance of skin, visibly reduce the outward signs of aging and minimize the appearance of pores. The product was sold to Bellus Medical (now Crown Aesthetics) in 2017.
Photocure developed Cevira®, a photodynamic drug-device combination product in development for non-surgical treatment of high-grade cervical dysplasia. The product was out-licensed to Asieris Meditech Co., Ltd for development and commercialization in 2019.